Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × Sodium Chloride × Clear all

Phase

Status

Unknown 1 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 3 Melanoma 3 Breast Neoplasms 3 Pain, Postoperative 2 Lung Neoplasms 2 Brain Neoplasms 2 Thoracic Neoplasms 1 Surgical Wound 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Neoplasms 1 Meningioma 1 Locally Advanced Head and Neck Squamous Cell Carcinoma 1 Leiomyoma 1 Hemorrhage 1 Hematologic Neoplasms 1 Gastrointestinal Neoplasms 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Chronic Pain 1 Atrial Fibrillation 1

Interventions

venetoclax 19 Cyclophosphamide 17 pembrolizumab 15 Dexamethasone 14 Cytarabine 12 fludarabine 11 Azacitidine 10 Gemcitabine 9 pomalidomide 7 Rituximab 7 Carboplatin 7 selinexor 6 glofitamab 6 Temozolomide 6 Lenalidomide 6 Granulocyte Colony-Stimulating Factor 6 fludarabine phosphate 5 Paclitaxel 5 Oxaliplatin 5 Injections 5 Cisplatin 5 zanubrutinib 4 ruxolitinib 4 obinutuzumab 4 daratumumab 4 carfilzomib 4 Surgical Procedures, Operative 4 Nivolumab 4 Decitabine 4 Cladribine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05899465 2025-03-18

PRIME

University of Aarhus

Phase 3 Recruiting

Melanoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡